Herling, Carmen Diana <br/><br/>
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.  [electronic resource] 

 -  Blood  07 2016 
 - 395-404 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2016-01-691550  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abnormal Karyotype<br/>Aged<br/>Aged, 80 and over<br/>Chlorambucil--administration & dosage<br/>Female<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Rituximab--administration & dosage<br/>Shelterin Complex<br/>Telomere-Binding Proteins--genetics